Drug Profile
AV 0113
Alternative Names: AV-0113; Cancer vaccine - Activartis; Cancer vaccine - Trimed; Dendritic cell vaccine - Activartis; Trivax cancer vaccineLatest Information Update: 12 Sep 2021
Price :
$50
*
At a glance
- Originator Trimed Biotech
- Developer Activartis Biotech
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours
Most Recent Events
- 08 Sep 2021 No development reported - Phase-II for Glioblastoma (Combination therapy, First-line therapy, Adjuvant therapy) in Austria (Intralymphatic)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Prostate-cancer in Austria (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Sarcoma in Austria (Parenteral, Injection)